CClinicalTrials.gg
TerminatedNCT06293495Updated Sep 25, 2026

Incidence of Cut-out Using Intramedullary Nails With Double Cephalic Screw vs. Unique in Pertrochanteric Fractures

An interventional study of Gamma 3 Nail (Stryker) and Chimaera Nail (Orthofix) in Proximal Femoral Fractures, sponsored by Puerta de Hierro University Hospital. Terminated at 1 site in Spain. Open to participants aged 70 Years and older. Per ClinicalTrials.gov, last updated 2026-09-25.

Sponsored by Puerta de Hierro University Hospital · Not applicable, Interventional, and Treatment

Why this study was terminated
The study was terminated early because of limited clinical use of the intramedullary nail with two cephalic screws, resulting in insufficient participant recruitment.
Phase
Not applicable
Study type
Interventional
Enrollment
200
Allocation
Randomized
Ages
70 Years and older
Sex
All
01

Study summary

The goal of this clinical trial is to compare outcomes in the treatment of proximal femur fractures. The main question it aims to answer is whether the use of a double cephalic screw prevents nail failure (cut-out).

Participants will be treated using open reduction and internal fixation with a proximal femoral nail. Researchers will compare intramedullary nailing with a single cephalic screw (Gamma nail) and with a double cephalic screw (Chimaera nail) to see the cut-out rate.

Read the detailed description

Randomized, open and prospective clinical trial.

Following the surgical indication for open reduction and internal fixation as treatment for proximal femoral fractures, patients will be randomly assigned (ratio 1:1) to one of the following treatments:

Control group: a Gamma 3 nail (single cephalic screw system) will be used for osteosynthesis of the fracture.

Experimental group: a Chimaera nail (system with double cephalic screw) will be used for osteosynthesis of the fracture.

Patient (or their legal guardian) must provide/sign the informed consent prior to inclusion in the study.

After the surgery, patients will be followed-up at 6 weeks, 3 and 6 months. At those times, data related to the radiological examination, the appearance of complications and the walking ability evaluation scale (FAC) will be collected.

02

Conditions studied

  • Proximal Femoral Fractures

Browse trials for

Keywords

  • Proximal femoral fracture
  • Hip fracture
  • Cut-out
03

Who can participate

Ages eligible
70 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Patients with proximal femur fracture (OTA/AO 31-A1, A2 and A3) requiring surgical treatment.
  • Signing of written informed consent according to current legislation before collecting any information, either by the patient or by the legal representative or by people linked by family ties.

Exclusion criteria

Exclusion Criteria:

  • Presence of other fractures in the ipsilateral femur that condition the surgical treatment of the pertrochanteric femur fracture.
  • Subcapital fracture of the proximal femur.
  • Subtrochanteric fracture of the proximal femur.
  • Pathological fracture.
04

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
200 participants (actual)

Study arms

  • Active comparator
    Single Cephalic Screw System

    A Gamma 3 nail (single cephalic screw system) will be used for osteosynthesis of the fracture.

    Device: Gamma 3 Nail (Stryker)

  • Experimental
    Double Cephalic Screw System

    A Chimaera nail (system with double cephalic screw) will be used for osteosynthesis of the fracture.

    Device: Chimaera Nail (Orthofix)

Interventions

  • DeviceGamma 3 Nail (Stryker)

    Open reduction an internal fixation of proximal femoral fracture with a Gamma 3 nail (single cephalic screw system)

  • DeviceChimaera Nail (Orthofix)

    Open reduction an internal fixation of proximal femoral fracture with a Chimaera nail (system with double cephalic screw)

05

What researchers measure

Primary outcomes

  1. Incidence of cut-out.

    Cut-out is a mechanical complication consisting of varus collapse and migration of the cephalic screw through the femoral head.

    Time frame: 0-6 months

Secondary outcomes

  1. Functional Ambulatory Categories (FAC)

    Classifies patients into 6 categories based on their ability and need for assistance with ambulation. Classifies patients into 6 categories based on their ability and need for help with ambulation, where 0 is equivalent to a patient with the impossibility of ambulation and 5 is a patient completely independent for ambulation.

    Time frame: 0-6 months

  2. Tip-apex distance

    Distance from the tip of the screw to the apex of the femoral head in the anteroposterior and axial views.

    Time frame: 3-6 months

  3. Parker index

    Indicates the distance of the screw from the inferior edge of the femoral neck in anteroposterior view or from the posterior edge of the femoral neck in lateral view.

    Time frame: 3-6 months

  4. Baumgaertner reduction quality criteria

    3 groups are established according to the quality of reduction: good, acceptable and bad

    Time frame: 3-6 months

  5. Number of Surgical complications (Intraoperative)

    Intraoperative complications

    Time frame: 0-1 month

  6. Number of Surgical complications (post-operative)

    Postoperative complications

    Time frame: 0-6 months

06

Study locations

1 site
  • Hospital Universitario Puerta de Hierro Majadahonda
    Majadahonda, Madrid 28222, Spain
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT06293495
Lead sponsor
Puerta de Hierro University Hospital
Responsible party
Pedro-José Torrijos-Garrido (Principal Investigator, Puerta de Hierro University Hospital) — Principal investigator
First posted
Mar 5, 2024
Start date
Mar 1, 2024
Primary completion
Jan 12, 2026
Completion
Jan 12, 2026
Last update
Sep 25, 2026

Study contacts

Pedro José Torrijos Garrido, MD, PhD
principal investigator · Study Principal Investigator

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion